Difluprednate
Clinical data | |
---|---|
Trade names | Durezol |
AHFS/Drugs.com | Monograph |
MedlinePlus | a609025 |
License data |
|
Routes of administration | Eye drops |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
JSmol) | |
| |
| |
(what is this?) (verify) |
Difluprednate, sold under the brand name Durezol, is a corticosteroid used for the treatment of post-operative ocular inflammation and pain.[1]
It was approved for medical use in the United States in June 2008.generic medication.[4]
Medical uses
Difluprednate is
indicated for the treatment of inflammation and pain associated with ocular surgery; and the treatment of endogenous anterior uveitis.[1]
Clinical trials
Difluprednate ophthalmic emulsion 0.05% is also being studied in other ocular inflammatory diseases, including a phase 3 study evaluating difluprednate for the treatment of anterior uveitis[5][6]
References
- ^ a b c d "Durezol emulsion". DailyMed. 11 July 2022. Retrieved 7 March 2023.
- ^ "Drug Approval Package: Durezol (Difluprednate) NDA #022212". U.S. Food and Drug Administration (FDA). 25 July 2008. Retrieved 7 March 2023.
- ^ "Sirion Therapeutics Announces FDA Approval of Durezol for Treatment of Postoperative Ocular Inflammation and Pain" (Press release). Sirion Therapeutics, Inc. 2008-06-24. Retrieved 2008-06-30.
- ^ "Competitive Generic Therapy Approvals". U.S. Food and Drug Administration (FDA). 29 June 2023. Archived from the original on 29 June 2023. Retrieved 29 June 2023.
- ^ Clinical trial number NCT00501579 for "Study of Difluprednate in the Treatment of Uveitis" at ClinicalTrials.gov
- PMID 24677110.